Aziyo Biologics, Inc. Announces Board Appointments
September 22, 2020 at 02:34 am IST
Share
Aziyo Biologics, Inc. announced that Maybelle Jordan, Vice President of Business Development of Biomerix Corporation, and Brigid Makes, former Senior Vice President and Chief Financial Officer of Miramar Labs, have joined its board of directors. Maybelle Jordan has served as Vice President of Business Development of Biomerix Corporation since 2011, and as Chief Operating Officer for Biomerix from 2003 to 2011. She also co-founded and served as President and CEO of MTrap Inc. from 2015 to 2019. Brigid A. Makes has served as an independent consultant for medical device and healthcare companies since July 2017, specifically advising on finance, accounting and funding responsibilities. From September 2011 to July 2017, Ms. Makes served as Senior Vice President and Chief Financial Officer of Miramar Labs, Inc. Prior to that, she served as Senior Vice President and Chief Financial Officer of AGA Medical Corp. Prior to joining AGA, Ms. Makes held various positions at Nektar Therapeutics Inc. from 1999 to 2006, including serving as Chief Financial Officer. Since December 2019, she has also served as a member of the board of directors of Mind Medicine (MindMed) Inc.
Elutia Inc. is a commercial-stage company, which has developed a portfolio of products using both human and porcine tissue. Its portfolio of products spans the Device Protection, Womenâs Health and Cardiovascular markets. These products are primarily sold to healthcare providers or commercial partners. In Device Protection, it sells CanGaroo, a biological envelope, that is indicated for use with implantable electronic devices, including cardiac and neurostimulator devices. In Womenâs Health, it has developed both patented and proprietary technologies, culminating in the creation of SimpliDerm, a biological matrix designed to leverage the inherent science of natural healing processes. In Cardiovascular, it sells its specialized porcine small intestine submucosa, which is also the tissue used to make CanGaroo, for use as an intracardiac and vascular patch, as well as for pericardial reconstruction. In addition, its TYKE product is designed for use in the neonatal patient population.
ELUTIA INC. 
